During the past five years considerable attention has been directed toward the sleep apnoea syndromes and the different types of apnoea observed during sleep (Guilleminault et al., 1976b) . Specu- lation about the possible lethal role played by sleep apnoea in infants (Sudden Infant Death syndrome) (Robinson, 1974) , and in adults (MacGregor et al., 1970) has led to systematic studies of sleep apnoeic patients. Haemodynamic changes occurring with upper airway apnoea during sleep (Coccagna et al., 1972; Tilkian et al., 1976) , and the clinical symptoms associated with this syndrome in children (Guilleminault et al., 1976a) and adults (Guilleminault et al., 1977) have been outlined but very little is known about the underlying pathophysiology. Excessive daytime sleepiness has been demonstrated to be related to predominantly upper airway apnoea in sleep rather than to diaphragmatic paralysis (Guilleminault and Dement, 1977) . The upper airway obstruction traditionally has been regarded as peripheral in aetiology, but Chekroverty et al. (1969) have sug-gested a central disturbance. This report outlines some factors favouring a central nervous system involvement in the upper airway/obstructive sleep apnoea syndrome.
Patient population and clinical symptomatology
From November 1974 to January 1976, 11 male patients, who gave informed consent to experiments (approved by the Stanford University School of Medicine Committee on the Use of Human Subjects in Research), participated in a specific study during wakefulness and sleep, conducted in collaboration with the Department of Cardiology.
The patients' ages ranged from 31 to 58 years (mean 44). All patients were referred to the Sleep Disorders Clinic for a complaint of excessive daytime sleepiness which had been present for two to 20 years before referral. Excessive daytime sleepiness was associated with hypnagogic hallucinations in 10 cases, but none presented with cataplexy or sleep paralysis. Eight patients had received dextroamphetamine or methylphenidate for several years without relief from the sleepiness. (Guilleminault et al., 1975b) .
On the fourth day each patient underwent right heart catheterisation. Swan-Ganz thermodilution catheters were positioned in the right pulmonary artery, and a polyethylene catheter was introduced into a femoral artery. The intravascular catheters were kept open by a continuous flush system, and patients were left undisturbed for 10-12 hours after 2200. Pulmonary arterial pressure (PAP) and systemic arterial pressure were continuously monitored on a Honeywell strip chart recorder. Arterial pressures and ECG were recorded on a Sony tape recorder.
For 12 hours on the second night and for 24 hours that included the haemodynamic monitoring, the ECG was monitored continuously in each patient using a portable single channel Avionics recorder. All ECG tapes were processed by computer methods described previously (Tilkian et al., 1976) . One patient (case 7) also received an intravenous injection of atropine sulphate (1 mg) during an early morning period of rapid eye movement (REM) sleep at the end of his haemodynamic study (day 4).
Several months after the study, five patients (cases 2, 3, 4, 5, and 9) underwent two successive all-night recordings of sleep and respiration, including a 24 hour ambulatory ECG recording.
Oral atropine sulplhate (1.2 mg) was adm,nistered just before the onset of sleep and again at 0200.
Patient 11 underwent an identical four day programme. On the fourth day, right heart catheterisation was followed by specific interventions and drug trials [ (Table) . The three types of apnoea (central, mixed, and obstructive) that have been described in the literature (Tassinari et al., 1972) were seen in each patient on any given night. However, 90.9% of the air exchange pauses during sleep were related to obstructive sleep apnoea; 3.35% and 5.75%
were central and mixed respectively. (Case 11: 91%, 4%, and 5% respectively). These results were in accordance with previous reports of other sleep apnoeic patients (Sackner et al., 1974; Guilleminault et al., 1975a; 1975b; Tilkian et al., 1976 (Bannister et al., 1967) . The response to intravenous atropine sulphate indicated some residual parasympathetic innervation of the heart. During sleep, in contrast to the other sleep apnoeic patients, case 11 had a slight decrease in systemic blood pressures and moderate pulmonary hypertension.
ARRHYTHMIAS AND SLEEP
During sleep, marked sinus arrhythmias were seen in cases 1-10. These arrhythmias were characterised by progressive sinus bradycardia levels of 25 beats per minute during apnoea and sinus tachycardia up to 120 beats per minute at resumption of respiration. More severe arrhythmias were observed in some patients. Apnoea and sinus bradycardia were accompanied by ventricular premature contraction in six patients, asystole in two patients (for 3.5 and 6.5 seconds) (see Fig. 3 ), second degree heart block in two patients, and ventricular tachycardia in one patient. None of these marked sinus arrhythmias or more severe ones were seen during REM sleep in cases 2 and 6 (Group A). Case 11 presented phasic minute-by-minute heart rate variations in association with apnoea and resumption of respiration, but the cyclical pattern was blunted. Sinus rate ranged from 65 to 90 per minute during sleep, in direct relationship to obstructed respiration and resumption of normal air exchange. 
IOs ACTION OF ATROPINE SULPHATE
The intravenous injection of atropine sulphate in patient 7 induced no change in respiration, apnoea, or sleep. There was a transient damping of systemic pressure variation which developed three minutes after injection and lasted for 20 minutes. Simultaneously, sinus tachycardia intervened with abolition of marked sinus arrhythmia. The five patients (cases 2, 3, 4, 6, and 9) who received oral atropine sulphate presented blunting of sinus bradycardia and accentuation of sinus tachycardia (Fig. 4) Oppenheimer, 1972) with associated mild neuropathy, and with gliosis in the raphe nuclei of the brain stem. 
Comments
Awareness that the control of respiration is critically dependent on sleep states has developed progressively during recent years. Bolton and Herman (1974) , Hathorn (1974) , and Finer et at. (1976) Guilleminault et at., 1976b for review) during the past 10 years. Recently, the possible involvement of the tongue in this obstructive process has been questioned. Sauerland and Harper (1976) Finally, a sleep apnoea syndrome may considerably reduce the life expectancy of patients with the Shy-Drager syndrome. Although this complication is not often suspected in these patients, it may not be uncommon. 
